We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.99B
AUM Growth
-$1.5B
Cap. Flow
-$539M
Cap. Flow %
-10.81%
Top 10 Hldgs %
44.72%
Holding
159
New
13
Increased
22
Reduced
36
Closed
24

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$47.6M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$33.3M
3
NVRO
NEVRO CORP.
NVRO
+$32.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$32.1M
5
PEN icon
Penumbra
PEN
+$31.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$46.5M
4
KOD icon
Kodiak Sciences
KOD
+$44.1M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$37.1M

Sector Composition

Rank Sector Weight
1 Healthcare 81.81%
2 Financials 0.77%
3 Industrials 0.12%
4 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLSA
76
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$9.87M 0.2%
1,000,000
– –
SMIHU
77
DELISTED
Summit Healthcare Acquisition Corp. Units
SMIHU
$9.78M 0.2%
1,000,000
– –
RACB
78
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$9.76M 0.2%
1,000,000
– –
ICVX
79
DELISTED
Icosavax, Inc. Common Stock
ICVX
$9.71M 0.19%
1,379,137
-527,411
-28% -$8.29M
FUSN
80
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$9.53M 0.19%
1,227,017
– –
PNT
81
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$9.52M 0.19%
1,193,995
– –
NUVB icon
82
Nuvation Bio
NUVB
$2.29B
$9.31M 0.19%
1,769,701
-1,151,122
-39% -$6.47M
ATXS
83
DELISTED
Astria Therapeutics
ATXS
$8.6M 0.17%
1,281,197
– –
EVH icon
84
Evolent Health
EVH
$371M
$8.07M 0.16%
+250,000
New +$6.55M
SNCE
85
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$8.03M 0.16%
75,000
– –
NBTX
86
Nanobiotix
NBTX
$1.92B
$7.88M 0.16%
1,059,800
– –
WGS icon
87
GeneDx Holdings
WGS
$1.89B
$7.67M 0.15%
75,758
– –
CNCE
88
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.25M 0.15%
2,150,641
– –
FULC icon
89
Fulcrum Therapeutics
FULC
$241M
$6.96M 0.14%
294,118
– –
ACAD icon
90
Acadia Pharmaceuticals
ACAD
$4.51B
$6.9M 0.14%
284,853
-1,299,199
-82% -$31.4M
ACRS icon
91
Aclaris Therapeutics
ACRS
$715M
$6.61M 0.13%
383,239
-397,997
-51% -$5.43M
PYXS icon
92
Pyxis Oncology
PYXS
$185M
$6.18M 0.12%
1,528,812
-415,302
-21% -$3.04M
ACCD
93
DELISTED
Accolade Inc
ACCD
$5.81M 0.12%
330,682
+101,908
+45% +$1.88M
PRVB
94
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$5.79M 0.12%
791,549
-156,932
-17% -$938K
PRVA icon
95
Privia Health
PRVA
$3.04B
$5.71M 0.11%
+213,423
New +$5.04M
MRUS
96
DELISTED
Merus
MRUS
$5.53M 0.11%
209,046
-140,954
-40% -$3.78M
DAWN
97
DELISTED
Day One Biopharmaceuticals
DAWN
$5.52M 0.11%
556,047
– –
CLOV icon
98
Clover Health Investments
CLOV
$2.23B
$5.33M 0.11%
1,500,000
– –
HYPR icon
99
Hyperfine
HYPR
$88.4M
$5.31M 0.11%
1,500,000
– –
TYRA icon
100
Tyra Biosciences
TYRA
$1.85B
$5.29M 0.11%
494,403
-178,949
-27% -$2.12M
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Perceptive Advisors held 159 positions worth $4.99B, down 23% from $6.49B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $539M in Q1 2022, closing 24 positions and reducing 36 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in CinCor Pharma, Inc. Common Stock worth $40.7M.

  • Perceptive Advisors's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 2,319,117 shares worth $40.7M.
  • Perceptive Advisors added most to NEVRO CORP. in Q1 2022, an estimated $32.7M increase.
  • Perceptive Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $92.4M.
  • Perceptive Advisors fully exited BioMarin Pharmaceuticals in Q1 2022, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $4.99B portfolio in Q1 2022.
  • Perceptive Advisors opened 13 new positions and closed 24 in Q1 2022.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $4.99B.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.